The EDB Gateway: Economic Development, the Biomedical Sciences Strategy, and Incentives

4.1 Introduction: The Front Door to Singapore

If you are a European pharmaceutical, medical device, or biotechnology firm seriously evaluating Singapore, there is one institution you will meet before almost any other, and one you will keep meeting for as long as you operate here. It is the Economic Development Board.

The previous chapter dealt with the regulator, because in biomedical the quality and predictability of the regulator is the foundation of the business decision. This chapter deals with the agency that turns a decision into an establishment. The Health Sciences Authority decides whether your product can be sold and your facility can operate. The EDB is the body that helps you decide to come at all, that shapes the economics of coming, and that stays with you afterwards.

It helps to be clear about what kind of body the EDB is, because it is unlike anything most European firms have dealt with at home. It is a statutory board established on 1 August 1961, sitting under the Ministry of Trade and Industry, charged with planning and executing the strategies that keep Singapore a location global firms want to invest in.^{1 2} Industries within its purview account for more than a third of Singapore’s annual gross domestic product.³ It is not a chamber of commerce and it is not a marketing office. It is an instrument of national industrial policy with the standing, the budget, and the institutional memory that go with sixty-five years of doing one job.

This chapter is your guide to that gateway. It explains what the EDB does, how its biomedical sector team works, what the agency’s strategy for the sector is and why that strategy should shape your thinking, how a European firm actually engages the agency, what the incentives are and what they require in return, and where the honest limits of any written account of the EDB lie. The last point matters more here than in most chapters, and the chapter says so plainly when it reaches it.

4.2 What the EDB Does, and the Biomedical Sciences Sector Team

The EDB’s job, reduced to its essentials, is to identify the sectors Singapore wants to grow, to design the conditions that attract serious firms in those sectors, and to engage those firms directly. In practice that means several distinct kinds of work carried out by the same agency: investment promotion, the design and administration of incentive packages, coordination with the agencies that allocate land and approve facilities, and the long aftercare relationship with firms once they have arrived.

The point for a European decision-maker is that these functions sit inside one body. In many countries a firm seeking to establish a regulated manufacturing site would deal with an investment-promotion agency, a separate tax authority, a separate land or planning authority, and a separate sector ministry, with no single party accountable for the whole. The EDB does not eliminate the other agencies, and this book is honest in later chapters that the regulator, the tax authority, and the land agency each remain distinct and must each be satisfied on their own terms. But the EDB functions as the coordinating counterpart, the body whose interest is in seeing the whole investment succeed rather than in clearing one administrative step.

What makes the EDB usable rather than merely large is that it organises itself around sectors, and biomedical sciences has its own dedicated team. A European biotechnology firm is not handed to a generalist who learns the sector from a briefing note. It engages people whose work is the biomedical industry, who understand the difference between a small-molecule manufacturing investment and a cell-and-gene-therapy investment, who know which research institutes and which healthcare partners are relevant to a given therapeutic area, and who have seen comparable firms make comparable decisions before. For a sector where the institutional landscape is the decision, as this book argues throughout, a counterpart who already knows that landscape is a material advantage.

The sector team is also the channel through which the EDB’s strategy for biomedical reaches an individual firm. The agency does not pursue every biomedical investment equally. It pursues the investments that fit the strategy it has set for the sector, and the conversation with a firm is, in large part, a conversation about how that firm’s plans fit. Understanding the strategy is therefore not background reading. It is preparation for the engagement itself, which is why the next section sets it out.

4.3 The Biomedical Sciences Industry Strategy

Singapore’s biomedical strategy is now in its third decade, and the most useful thing a European firm can understand about it is its direction of travel. The sector began, around the turn of the century, as an effort to attract pharmaceutical manufacturing. It has since moved steadily up the value chain, toward research and development, regional headquarters activity, intellectual-property ownership, and the newer therapeutic modalities, while retaining and deepening the manufacturing base it started with.

The manufacturing base is real and worth stating plainly, because it anchors everything else. In 2023 the biomedical sciences sector contributed 2.6 per cent of Singapore’s gross domestic product and manufactured products valued at close to 38 billion Singapore dollars for global markets.⁴ Biopharmaceutical manufacturing alone accounted for output in the high teens of billions of Singapore dollars.⁵ The EDB reports that the biopharmaceutical manufacturing talent pool has grown by 55 per cent over the past decade to around 9,500 professionals.⁶ These are not the numbers of a country trying to start a sector. They are the numbers of a country that has one and is moving it upmarket.

The physical infrastructure tells the same story. Two purpose-built estates anchor the sector. Tuas Biomedical Park, developed by JTC Corporation, provides ready access to power, water, telecommunications, and shared utilities so that biopharmaceutical companies can establish operations quickly and scale as they grow; it spans some 246 hectares and hosts a roster of the largest manufacturers in the field.^{7 8} Biopolis, at the one-north precinct, is the research counterpart, a campus where public research institutes, biotechnology startups, and multinational research operations sit alongside one another.⁹ The two estates correspond to the two halves of the strategy: Tuas for manufacturing at scale, Biopolis for the research and discovery the manufacturing increasingly draws on. Chapter 6 takes up the geography in detail, and Chapter 7 the specialised property; here the point is only that the strategy has a physical form, and that form was built deliberately.

The direction the strategy is now pushing is toward higher-value activity and newer science. The funding architecture makes this concrete. Singapore organises its public research investment in five-year national plans, and the current one, the Research, Innovation and Enterprise 2030 plan launched in December 2025, commits about 37 billion Singapore dollars over five years, a level that has held at roughly one per cent of gross domestic product for close to two decades.^{10 11} Human Health and Potential is one of the four strategic domains the plan funds, alongside manufacturing and connectivity, urban solutions, and the digital economy.¹² Within the biomedical ambit the agencies have been emphasising precision medicine, healthy ageing, and the translational platforms that move discoveries toward products, including the Experimental Drug Development Centre, the Diagnostics Development Hub, and the Nucleic Acid Therapeutics Initiative.¹³ Chapter 5 gives these bodies their proper treatment as part of the research-and-innovation landscape; for the purposes of the EDB conversation, what matters is that they signal where Singapore wants its biomedical sector to go.

The reason a European firm should care about all of this is direct. The closer a firm’s proposed activity sits to the agency’s strategic priorities, the easier the incentive conversation tends to be, because the firm is offering Singapore something Singapore has already decided it wants. A firm proposing high-value manufacturing of a complex biologic, or a research operation in a priority modality, or a regional headquarters that will manage and grow Asian operations from Singapore, is proposing the kind of activity the strategy was written to attract. A firm proposing a thin presence with little local substance is not, and the conversation will reflect that. None of this is favouritism. It is a public agency allocating public resources according to a published strategy, which is exactly what it should do.

4.4 How a European Firm Actually Engages the EDB

Here the chapter reaches the part that the official sources describe least well, and it is worth being honest about that before going further. The EDB publishes its strategy, its incentive parameters, and its sector priorities. What it does not publish, and what no government source sets out, is the practical reality of how a firm makes productive first contact and how the relationship with the agency actually develops from there. The published material describes named account teams and a facilitative posture; it does not describe who a firm should call first, how the early conversations really run, or how a relationship matures from initial interest into a structured proposal. That gap is not an oversight in this chapter. It is a genuine feature of the landscape, and it is precisely the kind of knowledge that sits with people who have been through the process rather than in any document. The book’s broader argument about the value of experienced guidance rests in large part on gaps exactly like this one.

What can be said from the public record, and stated carefully, is the following.

The engagement is relationship-led rather than form-led. A European firm does not establish a Singapore biomedical operation by completing an application and waiting for a decision. It does so by entering a conversation with the agency, usually well before any binding commitment is made, in which the firm’s plans and Singapore’s strategy are fitted to one another. The EDB maintains an international office network, including a presence in Europe, precisely so that this conversation can begin close to the firm rather than requiring it to start cold in Singapore.¹⁴

The earlier that conversation begins, the more useful it tends to be. This is not a matter of preference shown to early callers. It is structural. The incentives the EDB administers are designed to influence investment decisions, and an agency has more it can constructively discuss with a firm that is still deciding than with one that has already hired its staff, signed its lease, and committed its capital. A firm that engages while its plans are still being formed can shape those plans around what Singapore can support; a firm that engages after the fact is asking the agency to reward decisions it has already made. The practical lesson, consistent across every account of the process, is to engage before binding spend, not after.

What the firm should bring to that conversation is also clear enough from the assessment criteria, treated in the sections below. The EDB wants to understand the substance of the proposed investment: the nature of the activity, the people it will employ and at what level, the expenditure it will generate in the local economy, the capital it will commit, and the capabilities it will build and keep in Singapore. A firm that arrives with a serious, specific account of these is in a position to have a serious conversation. A firm that arrives with aspiration and no substance is not.

[DAVID: This section is the practitioner heart of the chapter and is deliberately thin in the draft because the primary sources are silent here, by design. Please supply, from your CEA and navigational experience: (1) how first contact actually happens in practice for an inbound European biomedical firm, including the realistic routes in and the role of introductions and intermediaries; (2) what the early conversations are actually like in tone and substance, and how they differ from what a European firm expects; (3) the sequence by which a relationship matures from first interest into a structured proposal, and roughly how long that takes; (4) what well-prepared firms bring to the table that unprepared firms do not; and (5) one or two anonymised illustrations, if you have them, of how engagement timing changed an outcome. Keep all of this in the facilitation-and-responsiveness register, never favour or rule-bending. This is the differentiated content that the public sources cannot provide and that justifies the chapter.]

4.5 EDBI and the Investment Dimension

Alongside its work on incentives and facilitation, the EDB has an investment arm, and a European biomedical firm may encounter it. EDBI, established in 1991, is the dedicated corporate investment arm of the Economic Development Board.¹⁵ It is a global venture and growth investor that deploys what it describes as patient capital, taking equity stakes in high-growth technology companies, including biomedical firms, that are looking to anchor or expand in Asia through Singapore.¹⁶ It now operates under SG Growth Capital, the joint investment platform of the EDB and Enterprise Singapore.¹⁷

EDBI’s place in the biomedical story is older than its current form. In the early 2000s it created Bio*One Capital, a dedicated biomedical sciences investment fund, which helped catalyse Singapore’s early biotechnology sector before the arm restructured into its present shape as a broader technology investor.¹⁸ Today its remit spans several technology sectors, with health and the bio-based economy among them.¹⁹

For most European firms the investment dimension is a complement to the establishment decision rather than its centre. A firm comes to Singapore to manufacture, to research, or to headquarter its Asian operations; an equity relationship with EDBI, where one arises, sits alongside that as one element of how the firm is anchored, not as the reason it came. It is worth understanding that the option exists, that the government’s interest in a firm’s success can extend to a capital stake, and that this is one more respect in which the Singapore state engages with serious inbound firms as a long-term participant rather than a one-time host. The broader venture and healthcare-investment landscape a firm may encounter is wider than EDBI alone, but EDBI is the part of it that is an arm of the agency the firm is already talking to, which is why it belongs in this chapter.

4.6 The Incentive Framework: The Pioneer Certificate and the Development and Expansion Incentive

The two principal corporate-tax incentives the EDB administers are the Pioneer Certificate Incentive and the Development and Expansion Incentive. They are usually discussed together, they share a statutory home, and for a biomedical firm the choice between them turns mostly on the nature and stage of the activity. The general corporate-tax framework these incentives modify sits in the companion treatment in Book 1; here the concern is what the incentives offer a biomedical operation specifically.

Both incentives reward companies for growing capabilities and conducting new or expanded activities in Singapore, and both are open to firms carrying out global or regional headquarters activities, meaning the managing, coordinating, and controlling of a group’s business across the region.²⁰ That headquarters dimension is relevant to European firms establishing an Asian base in Singapore rather than only a single function.

The substantive difference between them is one of degree. An approved company under the Pioneer Certificate Incentive is eligible for a corporate-tax exemption on income from its qualifying activities; an approved company under the Development and Expansion Incentive is eligible instead for a concessionary tax rate on that income, against a headline corporate rate of 17 per cent.^{21 22} To qualify for a Pioneer Certificate specifically, a company must introduce into its industry technology, skill sets, or know-how that are substantially more advanced than the average prevailing in Singapore, and carry out new, pioneering activities that have not been undertaken by other companies at a scale that is substantive in economic contribution.²³ That is a demanding test, and it is meant to be. The Pioneer Certificate is the senior instrument, reserved for activity that genuinely advances what Singapore can do. The Development and Expansion Incentive is the more widely used instrument, suited to firms whose proposed activity is substantive and high-value but not, strictly, pioneering.

The Development and Expansion Incentive has also changed in a way European firms should understand, because the change is recent and it is a response to a development that affects large multinationals directly. Historically the incentive offered concessionary rates of 5 per cent or 10 per cent.²⁴ In the 2024 Budget the government announced an additional 15 per cent tier for the incentive, a change subsequently given legal effect through amendment of the governing Act, with the amending Bill passed in November 2024.^{25 26} The reason is the global minimum tax. Under the international Pillar Two rules, large multinational groups face a minimum effective tax rate of 15 per cent, and for such a group a 5 per cent concessionary rate no longer delivers the benefit it once did, because the difference would be collected as a top-up tax elsewhere. The new 15 per cent tier aligns the incentive rate with the global floor, preserving a meaningful concession for in-scope groups where the lower tiers would largely be eroded.²⁷ For a large European pharmaceutical group, this is not a technicality. It changes which tier of the incentive is worth pursuing, and it should be modelled against the group’s specific position rather than assumed.

The incentive period for both instruments is, in its initial grant, a limited number of years, with extension considered where a company commits to further expansion.²⁸ The duration, the rate, and the qualifying scope are not standard terms read off a schedule. They are settled in the engagement with the agency, against the firm’s specific commitments, which is the point at which the substantive-activity tests treated below become decisive.

4.7 The IP Development Incentive and Research Support

For biomedical firms whose value rests in proprietary science, the incentive that often matters most is the one addressed to intellectual property. The Intellectual Property Development Incentive exists to encourage the use and commercialisation of intellectual property that arises from research and development carried out in Singapore.²⁹

An approved company under the incentive is eligible for a concessionary tax rate on a defined percentage of its qualifying intellectual-property income, with the percentage determined by what is known as the modified nexus approach, an international standard set by the OECD that ties the benefit to the share of the underlying research and development the company itself carried out or had carried out for it on qualifying terms.³⁰ The qualifying income is specific: it is royalties or other income received as consideration for the commercial exploitation of elected qualifying intellectual-property rights, namely patents and copyrights subsisting in software, elected irrevocably into the incentive.³¹ The concessionary rates available are 5 per cent and 10 per cent, and, following the same 2024 Budget change that added a 15 per cent tier to the Development and Expansion Incentive, a 15 per cent tier for this incentive as well.^{32 33}

The design principle is worth pausing on, because it shapes how a firm should structure to benefit. The modified nexus approach means the incentive rewards intellectual property that is genuinely developed through research and development connected to Singapore, not intellectual property merely parked here. A firm that conducts substantive research in Singapore, generates patents from it, and commercialises those patents can access a low effective rate on the resulting income. A firm that holds intellectual property in Singapore without the underlying research presence cannot, because the nexus formula will not credit it. The incentive and the research presence are two halves of one structure, and the IP-structuring logic this implies is developed further in Chapter 8.

Beyond the intellectual-property incentive, a biomedical firm conducting research and development in Singapore can draw on broader research support. The principal mechanism in the tax system is the Enterprise Innovation Scheme, administered by the Inland Revenue Authority of Singapore, which provides enhanced tax treatment for qualifying activities including research and development. Under it, a total deduction of 400 per cent is available on the first 400,000 Singapore dollars of qualifying research-and-development expenditure incurred on qualifying research and development carried out in Singapore in a basis period, with the standard additional deduction continuing to apply above that threshold.³⁴ The scheme runs across the years of assessment 2024 to 2028.³⁵ For a firm whose Singapore activity is research-intensive, this materially changes the after-tax cost of doing that research locally, and it sits alongside the intellectual-property incentive rather than competing with it. The EDB also administers project-based research support outside the tax system for qualifying activity, which a firm should raise directly in its engagement with the agency rather than assume.

4.8 The Substantive Activity Tests

Every incentive described above carries conditions, and the conditions are the part a firm lives with for the life of the award. Understanding them early prevents the most common and most damaging mistake in this whole area, which is structuring for an incentive a firm cannot sustainably satisfy.

The tests are, at root, tests of real economic presence. The EDB awards incentives to companies that are prepared to make significant investments contributing to the economy or advancing capabilities, and it assesses applications against both quantitative and qualitative criteria.³⁶ The criteria that recur across the instruments are the employment a firm will create, including the skills, expertise, and seniority of that employment; the total business expenditure the firm will generate, which is the measure of the spin-off its presence brings to the local economy; and the firm’s commitment to growing capabilities such as technology, skill sets, and know-how in Singapore.³⁷ Manufacturing projects carry an additional requirement to commit to fixed-asset investment in plant, building, or equipment.³⁸

Two features of these tests deserve emphasis because European firms regularly underestimate them.

The first is that the published parameters describe what is required to qualify, not what is required to succeed. The criteria set out in the statutory materials are eligibility conditions. The commitments a firm actually makes in a negotiated award are settled in the engagement with the agency, and they reflect the agency’s assessment of what a serious investment of the proposed kind should involve. A firm that reads the published conditions and assumes the minimum will do is misreading the process. The award is shaped to the firm, and the firm should expect the commitments to be substantial in proportion to the benefit.

The second is that the headcount commitment, in particular, is frequently the binding constraint. For activity that is capital-light and people-light, a research or headquarters operation rather than a manufacturing one, the requirement to commit to skilled employment based in Singapore is often the condition that determines whether an incentive is realistic at all. A firm should know its own realistic hiring trajectory before it sits down, because that trajectory, more than the capital it can deploy, will frame what is available to it.

The honest counterpart of all this is the part a firm least wants to hear, and it is the same point this series makes about Singapore generally. Because the tests are real and the commitments are binding, a firm that cannot realistically meet them should not pursue the incentive. The conditions are tracked, and the consequences of failing to meet them are real, as the next section sets out. For a firm bringing genuine substance, the rigour is a feature: it means the agency on the other side of the table is serious, and the firms that receive incentives are the ones that earned them. For a firm without that substance, the same rigour is a trap that closes quietly over the years after approval.

4.9 The Incentive Relationship as a Multi-Year Commitment

It is tempting to think of an incentive as a thing a firm obtains, a rate it is granted and then enjoys. It is more accurate, and more useful, to think of it as a relationship a firm enters, with obligations and reporting that run for the life of the award.

The administrative reality makes this concrete. The Pioneer Certificate and Development and Expansion Incentives are subject to the provisions of the Economic Expansion Incentives (Relief from Income Tax) Act and its subsidiary legislation, and a company holding one must submit regular progress reports to the EDB so that its performance can be evaluated.³⁹ Across the incentive regimes, recipients are expected to demonstrate, on a continuing basis, that they are meeting the commitments on which the award was made. Singapore also expects companies to transact with related parties at arm’s length and to keep contemporaneous transfer-pricing documentation, to be produced to the Inland Revenue Authority of Singapore on request, a requirement that applies to all businesses but that has particular weight for an incentivised multinational moving income across borders.⁴⁰

The consequence of failure is not nominal. Where a company breaches a term or condition of its incentive, it is subject to potential revocation of the incentive and recovery of the associated benefits.⁴¹ An incentive can, in other words, be taken back, and the tax that was forgone can be recovered, if the firm does not deliver what it agreed. This is the mechanism that makes the substantive-activity tests of the previous section more than aspiration. They are conditions, and they are enforced.

Read correctly, this reframes the whole incentive conversation. An incentive is a commitment in both directions. Singapore commits to a favourable tax treatment; the firm commits to the substance that justifies it. The relationship is monitored, and it is meant to last. For a European firm, the practical implication is that the incentive should be entered with the same seriousness as any other multi-year commitment, with the obligations modelled as carefully as the benefits, and with an honest internal view of whether the firm will still be meeting the conditions in year five and beyond. The post-establishment management of this relationship, including the reporting cycle and the ongoing engagement with the agency, is the subject of Chapter 12. The point to carry forward from here is that the relationship does not end at approval. In a real sense it begins there.

4.10 Eight Mistakes European Firms Make with the EDB

Across the engagement, certain mistakes recur. They are worth stating directly, because each is avoidable and each is costly.

Engaging after the binding spend rather than before. The single most common and most expensive error is to hire, lease, and commit capital first, then approach the EDB for an incentive. By that point the firm is asking to be rewarded for decisions already made, and the agency has far less it can constructively offer. Engage while the plans are still being formed.

Reading the published conditions as the actual commitment. The statutory parameters are eligibility thresholds, not the terms of a negotiated award. A firm that assumes the minimum will satisfy the agency misreads the process and arrives underprepared for the substance the conversation will require.

Underestimating the headcount commitment. For research and headquarters operations especially, the requirement to commit to skilled employment in Singapore is often the binding constraint. A firm that has not worked out its realistic hiring trajectory cannot have a serious conversation about an incentive.

Structuring for an incentive the firm cannot sustainably satisfy. Securing an award against commitments the firm will not meet is worse than not securing one at all, because the conditions are tracked and the benefit can be recovered. The trap closes quietly, years after approval.

Treating the incentive as a grant rather than a relationship. The award carries continuing reporting and continuing obligations. A firm that obtains an incentive and then forgets the conditions until a progress report falls due has misunderstood what it entered.

Parking intellectual property without the research presence to support it. The Intellectual Property Development Incentive rewards intellectual property developed through research connected to Singapore, measured by the modified nexus approach. Holding intellectual property here without the underlying research will not access the benefit, and may attract unwelcome attention instead.

Ignoring the global minimum tax in the rate calculation. For a large group within the scope of the Pillar Two rules, the lower concessionary tiers may be substantially eroded by top-up tax collected elsewhere, while the 15 per cent tier may be the one that actually delivers value. The rate worth pursuing depends on the group’s own position and should be modelled, not assumed.

Confusing the EDB with the regulator, the tax authority, and the land agency. The EDB coordinates and facilitates, but it does not stand in for the Health Sciences Authority, the Inland Revenue Authority of Singapore, or the land agencies, each of which must be satisfied on its own terms. A firm that treats a good EDB relationship as sufficient will be surprised by the other counterparts it still has to meet.

4.11 Conclusion

The EDB is the gateway, and a firm experiences the Singapore establishment process very differently depending on how it engages the agency. A firm that engages early, brings real substance, fits its plans to a strategy it has taken the trouble to understand, and enters its incentive as the multi-year commitment it is will find the EDB a serious and capable counterpart. A firm that engages late, brings aspiration without substance, and treats an incentive as a grant to be collected will find the same agency far less able to help, and will discover the conditions it overlooked at the point they are enforced.

The honest limit of this chapter is the one stated in the middle of it. The published record describes the strategy, the incentives, and the criteria well. It does not describe how a relationship with the agency actually forms and develops, which is the part that most shapes a firm’s experience and the part that sits with people who have navigated the process rather than in any document. That is not a defect in the sources. It is the shape of the landscape, and it is a recurring theme of this book.

The next chapter maps the research-and-innovation institutional landscape that the EDB’s biomedical strategy is built on, the agencies, the institutes, and the healthcare clusters that a European firm engages as collaborators, infrastructure providers, and sources of talent.

Declarations

Competing interests: The author is a licensed real estate agent (Council for Estate Agencies, Singapore) affiliated with OrangeTee & Tie Pte Ltd, and a Singapore Mediation Centre-accredited mediator. The author has commercial interests in industrial and commercial real estate transactions facilitated through OrangeTee & Tie, including transactions involving the biomedical-sciences facilities and estates discussed in this chapter. These interests are openly disclosed. The analysis in this chapter has been written to be useful to the reader irrespective of whether the reader subsequently engages the author’s transactional services.

Funding: This work received no external funding.

Methodology: This chapter draws on the primary published materials of the Singapore Economic Development Board, including its incentive brochures and sector materials, its corporate investment arm EDBI, and the Inland Revenue Authority of Singapore, together with the governing statutory instruments, principally the Economic Expansion Incentives (Relief from Income Tax) Act and the Income Tax Act 1947 and its subsidiary legislation. Incentive rates, tiers, and conditions were verified against the administering agencies’ own current publications and the relevant statutes at the time of writing, because these terms change. Where the published record does not document a matter, in particular the practical pathway of engagement with the agency, the chapter states the limitation rather than supplying detail the sources do not support. Sections drawing on the author’s professional experience are identified as such.

Currency of analysis: The analysis is current as of the date of publication. Singapore’s incentive landscape changes, sometimes significantly, in response to international tax developments and to the Government’s periodic Budget statements. Incentive rates, tiers, qualifying conditions, and the substantive-activity requirements should be verified against the current publications of the Economic Development Board and the Inland Revenue Authority of Singapore, and against the governing statutes, at the time any decision is made. The figures for sector output, employment, and research funding reflect the most recent published data at the time of writing and are periodically updated by the Government.

About the Author

David Hoicka is a Singapore-licensed real estate agent (Council for Estate Agencies) affiliated with OrangeTee & Tie Pte Ltd, with a specialisation in industrial and commercial property for European inbound investment. He is also a Singapore Mediation Centre-accredited mediator, a civil engineer (Bachelor of Science, Massachusetts Institute of Technology), and the founder and publisher of Singapore Mediation Solutions, an academic publisher registered with Crossref (DOI prefix 10.66404) and with the National Library Board of Singapore. He has lived in Singapore as a permanent resident for over twenty-one years.

Scholarly identifiers: ORCiD 0000-0001-9082-0720; Wikidata Q137455251; ISNI 0000 0005 2886 676X; Google Scholar profile available.

About the Publisher

Singapore Mediation Solutions is an open-access scholarly publisher specialising in practical and analytical works for cross-border commercial practitioners with a focus on Asia-Europe industrial and commercial relations. Singapore Mediation Solutions is registered with Crossref (DOI prefix 10.66404), is a Singapore publisher with NLB-assigned ISBNs, and deposits all works in Zenodo for permanent open-access availability and in OCLC WorldCat for library catalogue accessibility.

Confidential Consultation

Readers who would like to discuss engaging the Economic Development Board, structuring a biomedical investment around Singapore’s incentive framework, or locating laboratory and manufacturing space in the biomedical estates in confidence may contact the author directly. The preferred channels are Signal and Telegram for confidentiality and ease of cross-border communication. Direct email is also available. Contact details are listed on singaporescienceparks.com. Initial consultations are conducted without obligation; the author’s role as principal advisor and the relationship to OrangeTee & Tie transactional execution are set out in a written engagement letter before any onward referrals are made.

References

---

Chapter ID: biobook-ch04 (Crossref DOI to be assigned upon deposit) Zenodo deposit: pending Published by Singapore Mediation Solutions, Singapore Open access under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)